PCE Home Study
2020 Vision: Implementing the New ADA 2020 Guidelines for GLP-1 RAs in Clinical Practice
Release Date: October 31, 2020
Expiration Date: October 30, 2021
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
program overview
Program Description
The effects of diabetes treatments on important non-glycemic outcomes, such as cardiovascular, renal, and hypoglycemia risk and on body weight have led to new clinical pathways for treatment. In 2020, the American Diabetes Association (ADA) released guidelines for type 2 diabetes (T2DM) that acknowledge these significant findings and expand the recommended use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) because of their multifactorial benefits in T2DM. This activity is designed to help practitioners implement these new guidelines into clinical practice, while involving the patient in the decision-making process.
Format
Clinical review and case study
Learning Objectives
After completing this activity, participants should be better able to:
- Describe the pathophysiology of T2DM and the clinical utility of incretin therapy in patients with T2DM
- Apply the 2020 ADA recommendations for GLP-1 RAs to the care of patients with T2DM who require better glucose control, weight mitigation, and/or cardiovascular disease risk reduction
- Partner with patients to use shared decision-making to select and improve adherence to therapies
Target Audience
NPs and PAs
Faculty
Davida F. Kruger, MSN, APN-BC, BC-ADM
- Certified Nurse Practitioner
- Division of Endocrinology, Diabetes, and Bone and Mineral Disorders
- Henry Ford Health System
- Detroit, Michigan
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until October 30, 2021. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Daniel Thibodeau, MHP, PA-C, Eastern Virginia Medical School, Norfolk, Virginia
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity was developed from a series of programs cosupported by educational grants from AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC; Genentech, a member of the Roche Group; Novo Nordisk Inc.; Sanofi Genzyme; and Sanofi Genzyme and Regeneron Pharmaceuticals.
This activity is supported by an educational grant from Novo Nordisk Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Kruger: advisory board: Eli Lilly and Company, Merck, Sanofi-Aventis; advisory board/research support/speakers bureau: Abbott, Dexcom, Novo Nordisk; advisory board/speakers bureau: BI-Lilly, Janssen; advisory board/stock: Pendulum Therapeutics; research support: The Leona M. and Harry B. Helmsley Charitable Trust, Lexicon Pharmaceuticals; speakers bureau: AstraZeneca, Insulet, Lilly, Valeritas.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: October 31, 2020
Expiration date: October 30, 2021
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 97220CPCE-7D